Janus 激酶 1 抑制剂阿布昔替尼治疗孤立性甲扁平苔藓：病例报告及文献复习。
Janus kinase 1 inhibitor abrocitinib for isolated nail lichen planus: a case report and literature review.
机构信息
School of Medicine, Nankai university, Tianjin, China.
Department of Dermatology, First Medical Center of Chinese PLA General Hospital, Beijing, China.
出版信息
J Dermatolog Treat. 2024 Dec;35(1):2434094. doi: 10.1080/09546634.2024.2434094. Epub 2024 Nov 27.
AIM
This study aims to evaluate the efficacy and safety of the Janus kinase 1 (JAK1) inhibitor abrocitinib for treating nail lichen planus (NLP) and to review available case reports documented in English.
METHODS
We reported the first case of a patient with isolated NLP treated with the selective JAK1 inhibitor abrocitinib. The patient received 100 mg of oral abrocitinib daily.
RESULTS
After 6 months, the patients showed 82.35% improvements in the Dermatology Life Quality Index (DLQI) and 79.17% improvement in the Nail lichen planus severity index (tNLPSI), which were consistent with the clinical improvement, correlating with clinical improvement. In the subsequent 6 months, the dose was reduced to 100 mg every other day, with further improvement in onycholysis.
CONCLUSIONS
This case suggests that abrocitinib can be both safe and effective for treating NLP.
目的
本研究旨在评估 Janus 激酶 1（JAK1）抑制剂阿布昔替尼治疗甲扁平苔藓（NLP）的疗效和安全性，并回顾已发表的英文病例报告。
方法
我们报告了首例接受选择性 JAK1 抑制剂阿布昔替尼治疗的孤立性 NLP 患者。患者每日接受 100mg 阿布昔替尼口服治疗。
结果
6 个月后，患者的皮肤病生活质量指数（DLQI）改善了 82.35%，甲扁平苔藓严重指数（tNLPSI）改善了 79.17%，与临床改善一致。在随后的 6 个月中，将剂量减少至 100mg 隔日一次，甲松解进一步改善。
结论
本病例提示阿布昔替尼治疗 NLP 安全且有效。
Zotero 插件